Stockscreener 앱 받기
5.05
1.41%
0.07
시장 영업 전:
5.05
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Stocktwits
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
Teva, Apotex Don't Infringe Sleep Drug Patents, Judge Finds - Law360
Teva, Apotex Beat Vanda Patent Claims Over Hetlioz Sleep Drug - Bloomberg Law News
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
VNDA Initiates Coverage On Oppenheimer -- Rating Outperform with $10.00 Price Target - GuruFocus
Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating - Investing.com
Vanda Pharmaceuticals stock slips as 2025 loss widens - AD HOC NEWS
Vanda Pharmaceuticals at H.C. Wainwright conference: pipeline broadens By Investing.com - Investing.com Canada
VNDA: BYSANTI and NEREUS launches, plus pivotal readouts, set up major growth opportunities ahead - TradingView
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
VNDA: BYSANTI and NEREUS launches, plus pipeline catalysts, set the stage for major revenue growth - TradingView
Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage - Investing.com Canada
VNDA: BYSANTI and NEREUS launches, plus key phase III trials, set the stage for major revenue growth - TradingView
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
Vanda Pharmaceuticals Inc. (VNDA) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
DC’s Vanda Pharmaceuticals Wins EU Orphan Status for Its Rare Skin Disease Drug - BioBuzz
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences - StreetInsider
Vanda Pharmaceuticals Inc. (VNDA) Peer Comparison – Compare with Others - valueresearchonline.com
Convert Vanda Pharmaceuticals Inc. (VNDA) to Canadian Dollar (CAD) - Crypto.com
Vanda Pharmaceuticals Mallorca Women's Championships 2026 Scores | Latest Scores & Live Updates – WTA Official - WTA Tennis
Millennium Management Expands Vanda Pharmaceuticals Stake Amid D - GuruFocus
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - PR Newswire
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. - Sahm
Millennium reports 3.38M-share passive stake in Vanda (NASDAQ: VNDA) - Stock Titan
DC Circuit Partially Rejects Vanda’s Fight of Generic Sleep Drug - Bloomberg Law News
Vanda Pharmaceuticals Inc (VNDA) (Q2 2026) Earnings Call Highlig - GuruFocus
Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044 - Pulse 2.0
AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G - Stock Titan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst - MarketBeat
VNDA Reiterated by B. Riley Securities -- Price Target Lowered t - GuruFocus
Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial - MarketBeat
B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating - marketscreener.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 - Investing.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 By Investing.com - Investing.com Canada
VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Pharmaceuticals Inc (VM4.DU) insider ownership and holdings - Yahoo Finance Australia
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $11 - moomoo.com
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st
3.06%
2.55%
자본화:
|
볼륨(24시간):